Arca
Skip to content
Tools
Tools

B-cell Non-Hodgkin's lymphoma

Drug research and approvals for B-cell Non-Hodgkin's lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 529 studies of B-cell Non-Hodgkin's lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 529
  • Trials authorized in Canada: 17
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 529 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 17; search them all in Canada trials
Apr 29, 2026A phase 1/2 open-label, multi-center study to evaluate the safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-cell…GSK5926371GSKOngoing
Jun 20, 2025An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /…Treeline BiosciencesOngoing
Sep 20, 2024A modular phase II, single-arm, multicenter, open-label study to evaluate the efficacy and safety of AZD0486 in participants with relapsed or refractory B-cell…AZD0486AstraZeneca PharmaceuticalsOngoing
Mar 8, 2024A phase 1b multicenter, open-label, study of JNJ-90014496, an autologous CD19/CD20 bi-specific CAR-T cell therapy in adult participants with relapsed or…JNJ-90014496Johnson & JohnsonOngoing
May 31, 2023A phase 1, open-label, multicenter, dose escalation study of PRT1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / Venetoclax / AzacitidinePrelude TherapeuticsClosed
May 30, 2023A phase I cohort dose escalation and expansion trial to determine the safety, tolerance, maximum tolerated dose, and preliminary antineoplastic activity of…IKS03Iksuda Therapeutics LimitedOngoing
Apr 11, 2022Long-term follow-up study for participants of kite sponsored interventional studies treated with gene modified cellsYescarta / TecartusKite, A Gilead CompanyPending
Mar 3, 2022A phase 1, open-label, dose-escalation and dose-expansion study of NL-201 in patients with B-cell lymphoma, Hodgkin lymphoma, or multiple myelomaNL-201Neoleukin Therapeutics Inc.Pending
Aug 4, 2021A phase Ib/II open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab with or…Mosunetuzumab (BTCT4465A; RO7030816) \ tiragolumab (RO7092284) \ atezolizumab…RocheClosed
Sep 3, 2020A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory…Lisocabtagene maraleucel (JCAR017)Bristol-Myers SquibbOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 19, 2002ZevalinTreatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients…Acrotech Biopharma LLCApproved
Nov 26, 1997RituxanTreatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphomaGenentech, Inc.Approved
Nov 27, 1998Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb…Treatment of B-cell non-Hodgkin's lymphoma.Peregrine Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.